Martyn Plummer

Martyn Plummer

Auto-generated profile, based on publicly available information

Martyn Plummer

International Agency for Research on Cancer, Lyon, France

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
CMCatherine de Martel
Catherine de Martel
MPMartyn Plummer
Martyn Plummer
JVJerome Vignat
Jerome Vignat
SFSilvia Franceschi
Silvia Franceschi
HPV is the cause of almost all cervical cancer and is responsible for a substantial fraction of other anogenital cancers and oropharyngeal cancers. Understanding the HPV‐attributable cancer burden can boost programs of HPV vaccination and HPV‐based cervical screening. Attributable fractions (AFs) and the relative contributions of different HPV types were derived from published studies reporting on the prevalence of transforming HPV infection in cancer tissue. Maps of age‐standardized incidence rates of HPV‐attributable cancers by country from GLOBOCAN 2012 data are shown separately for the cervix, other anogenital tract and head and neck cancers. The relative contribution of HPV16/18 and HPV6/11/16/18/31/33/45/52/58 was also estimated. 4.5% of all cancers worldwide (630,000 new cancer cases per year) are attributable to HPV: 8.6% in women and 0.8% in men. AF in women ranges from 20% in India and sub‐Saharan Africa. Cervix accounts for 83% of HPV‐attributable cancer, two‐thirds of which occur in less developed countries. Other HPV‐attributable anogenital cancer includes 8,500 vulva; 12,000 vagina; 35,000 anus (half occurring in men) and 13,000 penis. In the head and neck, HPV‐attributable cancers represent 38,000 cases of which 21,000 are oropharyngeal cancers occurring in more developed countries. The relative contributions of HPV16/18 and HPV6/11/16/18/31/33/45/52/58 are 73% and 90%, respectively. Universal access to vaccination is the key to avoiding most cases of HPV‐attributable cancer. The preponderant burden of HPV16/18 and the possibility of cross‐protection emphasize the importance of the introduction of more affordable vaccines in less developed countries.

1 June 2012 in The Lancet Oncology
Verified
Journal Article
Closed access
CMCatherine de Martel
Catherine de Martel
JFJacques Ferlay
Jacques Ferlay
SFSilvia Franceschi
Silvia Franceschi
JVJérôme Vignat
Jérôme Vignat
FBFreddie Bray
Freddie Bray
MPMartyn Plummer
Martyn Plummer

1 November 2012 in Vaccine
Verified
Journal Article
Closed access
DFDavid Forman
David Forman
CMCatherine de Martel
Catherine de Martel
CLCharles J. Lacey
Charles J. Lacey
ISIsabelle Soerjomataram
Isabelle Soerjomataram
JLJoannie Lortet-Tieulent
Joannie Lortet-Tieulent
SFSilvia Franceschi
Silvia Franceschi

1 September 2016 in The Lancet Global Health
Verified
Journal Article
Open access
MPMartyn Plummer
Martyn Plummer
CMCatherine de Martel
Catherine de Martel
JVJerome Vignat
Jerome Vignat
JFJacques Ferlay
Jacques Ferlay
FBFreddie Bray
Freddie Bray
SFSilvia Franceschi
Silvia Franceschi
Infections with certain viruses, bacteria, and parasites are strong risk factors for specific cancers. As new cancer statistics and epidemiological findings have accumulated in the past 5 years, we aimed to assess the causal involvement of the main carcinogenic agents in different cancer types for the year 2012. We considered ten infectious agents classified as carcinogenic to human beings by the International Agency for Research on Cancer. We calculated the number of new cancer cases in 2012 attributable to infections by country, by combining cancer incidence estimates (from GLOBOCAN 2012) with estimates of attributable fraction (AF) for the infectious agents. AF estimates were calculated from the prevalence of infection in cancer cases and the relative risk for the infection (for some sites). Estimates of infection prevalence, relative risk, and corresponding 95% CIs for AF were obtained from systematic reviews and pooled analyses. Of 14 million new cancer cases in 2012, 2·2 million (15·4%) were attributable to carcinogenic infections. The most important infectious agents worldwide were Helicobacter pylori (770 000 cases), human papillomavirus (640 000), hepatitis B virus (420 000), hepatitis C virus (170 000), and Epstein-Barr virus (120 000). Kaposi's sarcoma was the second largest contributor to the cancer burden in sub-Saharan Africa. The AFs for infection varied by country and development status-from less than 5% in the USA, Canada, Australia, New Zealand, and some countries in western and northern Europe to more than 50% in some countries in sub-Saharan Africa. A large potential exists for reducing the burden of cancer caused by infections. Socioeconomic development is associated with a decrease in infection-associated cancers; however, to reduce the incidence of these cancers without delay, population-based vaccination and screen-and-treat programmes should be made accessible and available. Fondation de France.

28 January 2003 in British Journal of Cancer
Verified
Journal Article
Open access
GCG M Clifford
G M Clifford
JSJ S Smith
J S Smith
MPM Plummer
M Plummer
NMN Muñoz
N Muñoz
SFS Franceschi
S Franceschi
This study investigated regional variations in the contribution made by different human papilloma (HPV) types to invasive cervical cancer (ICC). A total of 85 studies using polymerase chain reaction to estimate HPV prevalence in ICC were identified. Data on HPV prevalence were extracted separately for squamous cell carcinoma (SCC) and for adeno- and adenosquamous-carcinoma (ADC). A total of 10 058 cases (8550 SCC, 1508 ADC) were included in pooled analyses. The most common HPV types in ICC were, in order of decreasing prevalence, HPV16, 18, 45, 31, 33, 58, 52, 35, 59, 56, 6, 51, 68, 39, 82, 73, 66 and 70. In SCC, HPV16 was the predominant type (46–63%) followed by HPV18 (10–14%), 45 (2–8%), 31 (2–7%) and 33 (3–5%) in all regions except Asia, where HPV types 58 (6%) and 52 (4%) were more frequently identified. In ADC, HPV prevalence was significantly lower (76.4%) than in SCC (87.3%), and HPV18 was the predominant type in every region (37–41%), followed by 16 (26–36%) and 45 (5–7%). The overall detection of HPV DNA was similar in different regions (83–89%). A majority of ICC was associated with HPV16 or 18 in all regions, but approximately a quarter of all ICC cases were associated with one of 16 other HPV types, their distribution varying by region.

18 August 2016 in New England Journal of Medicine
Verified
Journal Article
Closed access
SVSalvatore Vaccarella
Salvatore Vaccarella
SFSilvia Franceschi
Silvia Franceschi
FBFreddie Bray
Freddie Bray
CWChristopher P. Wild
Christopher P. Wild
MPMartyn Plummer
Martyn Plummer
LMLuigino DAL MASO
Luigino DAL MASO
Dramatic increases have been seen over recent decades in the reported incidence of thyroid cancer, but owing to new modes of screening, hundreds of thousands of cases may be overdiagnoses — diagnosis of tumors that would not, if left alone, result in symptoms or death.